BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Williams JA. GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies. Pancreatology 2016;16:2-7. [DOI: 10.1016/j.pan.2015.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cakmak R, Caklili OT, Tekin S, Hacisahinogullari H, Tanrikulu S, Koc MS, Dinccag N. Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities. Biomark Med 2022;16:5-10. [PMID: 34856813 DOI: 10.2217/bmm-2021-0318] [Reference Citation Analysis]
2 Fine D. Special Section. Pancreatology 2016;16:1. [PMID: 26891820 DOI: 10.1016/j.pan.2016.01.008] [Reference Citation Analysis]
3 Liu Y, Tian Q, Yang J, Wang H, Hong T. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Diabetes Metab Res Rev. 2018;34:e3061. [PMID: 30109766 DOI: 10.1002/dmrr.3061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mikov M, Pavlović N, Stanimirov B, Đanić M, Goločorbin-Kon S, Stankov K, Al-Salami H. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. Eur J Drug Metab Pharmacokinet 2020;45:1-14. [PMID: 31385198 DOI: 10.1007/s13318-019-00570-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 McBrayer DN, Tal-Gan Y. Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus. Drug Dev Res 2017;78:292-9. [PMID: 28786125 DOI: 10.1002/ddr.21404] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
6 Musale V, Moffett RC, Conlon JM, Flatt PR, Abdel-Wahab YH. Beneficial actions of the [A14K] analog of the frog skin peptide PGLa-AM1 in mice with obesity and degenerative diabetes: A mechanistic study. Peptides 2021;136:170472. [PMID: 33338546 DOI: 10.1016/j.peptides.2020.170472] [Reference Citation Analysis]
7 Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD. Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. Diabetes Obes Metab 2019;21:1837-48. [PMID: 30945402 DOI: 10.1111/dom.13739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lakhanpal A, Brahn E. Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions. Clin Rheumatol 2016;35:2869-75. [PMID: 27714482 DOI: 10.1007/s10067-016-3430-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]